Glenn Liu, MD, is a clinical and translational researcher with expertise in drug and imaging biomarker development.
Dr. Liu previously led the Phase 1 research group and Developmental Therapeutics research program for the UW Carbone Cancer Center, thus has expertise in early drug development. He continues to lead the research activities within the Genitourinary oncology research group with focus on all phases of clinical trials. He also leads national efforts in drug and biomarker development within the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) and National Clinical Trials Network (NCTN).
Active Projects
Imaging Biomarkers of Treatment Response
Dr. Liu has a joint appointment in the Department of Medical Physics and collaborates with Dr. Robert Jeraj to develop imaging biomarkers of treatment response to aid drug development and clinical decision making. This research has led to understanding that while each patient may respond differently to specific treatment, every lesion within a patient can respond differently as well. This has led to the development of tools to characterize spatial-temporal change in all lesions, a workflow to perform treatment-response directed biopsies, and to predict benefit and toxicity to treatment.
This work has led to FDA FDA-cleared tool (TRAQinform IQ) used in patient care and multiple clinical trials, as well as a UW-spin-off company (AIQ-Solutions).
Funding Support
Dr. Liu has been continuously funded since 2008 by the National Institutes of Health (NCI), Department of Defense Prostate Cancer Research Program, and/or the Prostate Cancer Foundation.
